NDC 63187-348 Dexlido-m Kit

The NDC code 63187-348 is assigned by the FDA to the product Dexlido-m Kit which is product labeled by Proficient Rx Lp. The product's dosage form is . The product is distributed in a single package with assigned NDC code 63187-348-01 1 kit in 1 carton * 10 ml in 1 vial, single-dose (0409-1559-10) * .9 ml in 1 packet (67777-130-02) * 5 ml in 1 pouch (53329-820-09) * 2 ml in 1 ampule (0409-4713-32) * 1 ml in 1 vial (63323-506-01). This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

By intravenous or intramuscular injection when oral therapy is not feasible:1. Endocrine Disorders     Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids     where applicable; in infancy, mineralocorticoid supplementation is of particular importance).     Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs     are used).     Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.     Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.     Congenital adrenal hyperplasia      Nonsuppurative thyroiditis     Hypercalcemia associated with cancer2. Rheumatic Disorders     As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:     Post-traumatic osteoarthritis     Synovitis of osteoarthritis     Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).     Acute and subacute bursitis     Epicondylitis     Acute nonspecific tenosynovitis     Acute gouty arthritis     Psoriatic arthritis     Ankylosing spondylitis3. Collagen Diseases     During an exacerbation or as maintenance therapy in selected cases of:     Systemic lupus erythematosus     Acute rheumatic carditis4. Dermatologic Diseases     Pemphigus     Severe erythema multiforme (Stevens-Johnson syndrome)     Exfoliative dermatitis     Bullous dermatitis herpetiformis     Severe seborrheic dermatitis     Severe psoriasis     Mycosis fungoides 5. Allergic States     Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:     Bronchial asthma     Contact dermatitis     Atopic dermatitis     Serum sickness     Seasonal or perennial allergic rhinitis     Drug hypersensitivity reactions     Urticarial transfusion reactions     Acute noninfectious laryngeal edema (epinephrine is the drug of first choice).6. Ophthalmic Diseases     Severe acute and chronic allergic and inflammatory processes involving the eye, such as:     Herpes zoster ophthalmicus     Iritis, iridocyclitis     Chorioretinitis     Diffuse posterior uveitis and choroiditis     Optic neuritis     Sympathetic ophthalmia     Anterior segment inflammation     Allergic conjunctivitis     Keratitis     Allergic corneal marginal ulcers 7. Gastrointestinal Diseases     To tide the patient over a critical period of the disease in:     Ulcerative colitis (systemic therapy)     Regional enteritis (systemic therapy)8. Respiratory Diseases     Symptomatic sarcoidosis     Berylliosis     Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy.     Loeffler’s syndrome not manageable by other means.     Aspiration pneumonitis 9. Hematologic Disorders     Acquired (autoimmune) hemolytic anemia.     Idiopathic thrombocytopenic purpura in adults     (IV only; IM administration is contraindicated).     Secondary thrombocytopenia in adults     Erythroblastopenia (RBC anemia)     Congenital (erythroid) hypoplastic anemia10. Neoplastic Diseases     For palliative management of:     Leukemias and lymphomas in adults     Acute leukemia of childhood11. Edematous States     To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.12. Miscellaneous     Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.     Trichinosis with neurologic or myocardial involvement.13. Diagnostic testing of adrenocortical hyperfunction.14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury.  Use in cerebral edema is not a substitute for careful neurosurgical evaluation     and definitive management such as neurosurgery or other specific therapy.   Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. MARCAINE is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS.)Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of MARCAINE in these patients.MARCAINE is not recommended for intravenous regional anesthesia (Bier Block). See WARNINGS.The routes of administration and indicated MARCAINE concentrations are:∙ local infiltration                                                                                 0.25%∙ peripheral nerve block                                                                      0.25% and 0.5%∙ retrobulbar block                                                                              0.75%∙ sympathetic block                                                                             0.25%∙ lumbar epidural                                                                                 0.25%, 0.5%, and 0.75%                                                                                                          (0.75% not for obstetrical anesthesia)∙ caudal                                                                                               0.25% and 0.5%∙ epidural test dose                                                                              0.5% with epinephrine 1:200,000∙ dental blocks                                                                                     0.5% with epinephrine 1:200,000(See DOSAGE AND ADMINISTRATION for additional information.)Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of MARCAINE.

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:

• RxCUI: 1725078 - BUPivacaine HCl 0.25 % in 10 ML Injection
• RxCUI: 1725078 - 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection
• RxCUI: 1725078 - bupivacaine HCl 0.25 % in 10 ML Injection
• RxCUI: 1725079 - Marcaine 0.25 % in 10 ML Injection
• RxCUI: 1725079 - 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection [Marcaine]